 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ( ALX Oncology or the Company ) (Nasdaq: ALXO), an immuno-oncology company developing therapies that...

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation PR Newswire NEW YORK, Sept. 20, 2023...

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

For the last three days, A.I.dvisor has detected that ALXO's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

ALX Oncology Holdings (ALXO, $5.05) Aroon Indicator entered a Downtrend on September 12, 2023.

ALX Oncology Holdings (ALXO, $4.96) Aroon Indicator entered a Downtrend on September 11, 2023.

ALX Oncology Holdings (ALXO, $4.92) Aroon Indicator entered a Downtrend on September 08, 2023.

ALX Oncology Holdings (ALXO, $4.97) Aroon Indicator entered a Downtrend on September 07, 2023.

ALX Oncology Holdings (ALXO, $4.84) Aroon Indicator entered a Downtrend on September 06, 2023.

Jason Lettmann appointed as Chief Executive OfficerDr. Jaume Pons transitions to Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings...

ALX Oncology Realigns Executive Leadership Team

ALX Oncology Holdings (ALXO, $4.55) Aroon Indicator entered a Downtrend on September 05, 2023.

ALX Oncology Holdings (ALXO, $4.52) Aroon Indicator entered a Downtrend on September 01, 2023.

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.

Watchers	564
52-Wk Low	$3.94
52-Wk High	$13.64

Market Cap	$197.94M
Volume (M)	321,366.00
52-Wk High	$13.64
52-Wk Low	$3.94

ALXO Alx Oncology Holdings Inc

About

Feed

News

Sentiment

Earnings

Fundamentals